Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Interferon gamma | Actimmune | gamma interferon|IFN-G|recombinant interferon gamma | Interferon gamma is a cytokine that binds IFN-gamma receptors, leading to pleiotropic effects, including stimulating antibody-dependent cytotoxicity and enhanced natural killer cell activity against tumor cells and the activation of caspases, leading to apoptosis of malignant cells (PMID: 14525967). | |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Pertuzumab | Perjeta | 2C4 Antibody | HER2 (ERBB2) Antibody 76 | Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent dimerization and subsequent HER signaling, thereby resulting in apoptosis and tumor growth inhibition (PMID: 15699478). Perjeta (pertuzumab) is FDA approved in combination with Herceptin (trastuzumab) and Taxotere (docetaxel) for patients with ERBB2 (HER2)-positive breast cancer and in combination with Herceptin (trastuzumab) and chemotherapy as neoadjuvant treatment for patients with ERBB2 (HER2)-positive breast cancer (FDA.gov). |
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 76 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03112590 | Phase Ib/II | Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | Completed | USA | 0 |